INTERPACE BIOSCIENCES Business Summary

Interpace Biosciences, Inc. (IDXG) is a commercial-stage molecular diagnostics provider specializing in oncology-focused genomic testing and bioinformatics. As of early 2026, the company has streamlined its business model to focus exclusively on its thyroid testing franchise, following the discontinuation of its PancraGEN assay in May 2025. Revenue is primarily generated through a fee-for-service model, where the company receives reimbursements from third-party payers and medical centers for its flagship ThyGeNEXT® and ThyraMIR®v2 tests, which risk-stratify indeterminate thyroid nodules. This strategic pivot has resulted in a debt-free balance sheet and a transition toward sustained profitability, with 2026 revenue guidance projected at approximately $40 million. Direct competitors include Veracyte, Inc. (specifically the Afirma platform), Castle Biosciences, and NeoGenomics Laboratories. Within this landscape, Interpace maintains a specialized niche as a high-growth, pure-play thyroid diagnostics provider currently seeking an uplisting to the Nasdaq Stock Market. The leadership team is headed by President and CEO Thomas W. Burnell, PhD, who also serves as Chairman of the Board. Burnell, an Operating Partner at the healthcare investment firm 1315 Capital, brings extensive executive experience from previous roles as CEO of Eurofins Scientific, Inc. and GenomicFX. Supporting him are Christopher McCarthy, who serves as both Chief Financial Officer and Chief Operating Officer, and Sydney D. Finkelstein, MD, the Chief Scientific Officer and founder of RedPath Integrated Pathology. The company’s strategic direction is heavily influenced by its primary institutional backers, including 1315 Capital and Ampersand Capital Partners. The Board of Directors features notable industry veterans such as Ron Rocca, CEO of Exagen, and Dr. Vijay Aggarwal, providing deep expertise in clinical diagnostics and molecular pathology.